TNF and inflammatory bowel disease: Despite the licensing of new biologic drugs for IBD and increasing access to biologics across many healthcare systems,12–16 anti-TNFs have largely retained their position as preferred first-line advanced therapies for IBD.17 Major drivers have been the licensing of cheaper biosimilar anti-TNF agents and extensive experience with these drugs.